Drug Interactions between nafcillin and Trintellix

ADJUST DOSE: Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of vortioxetine, which is primarily metabolized by CYP450 2D6. According to the product labeling, administration of vortioxetine with the potent CYP450 inducer rifampin resulted in an approximately 50% decrease in vortioxetine peak plasma concentration (Cmax) and 75% decrease in systemic exposure (AUC) compared to administration of vortioxetine alone.

MANAGEMENT: An increase in the dosage of vortioxetine should be considered when used in combination with potent CYP450 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifamycins) for greater than 14 days, up to a maximum of three times the original dosage depending on clinical response. Following discontinuation of the potent CYP450 inducer, vortioxetine dosage should be returned to the original level within 14 days. Other known CYP450 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, enzalutamide, efavirenz, etravirine, nevirapine, somatrem, somatropin, suzetrigine, and various other anticonvulsants, although the extent to which they interact with vortioxetine is unknown. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised, and the vortioxetine dosage adjusted as necessary.